Policy | December 04, 2025
Promotion of indigenous pharmaceutical manufacturing
PLI scheme for Bulk Drugs has a total budgetary outlay of Rs. 6,940 crore
PLI scheme for Bulk Drugs has a total budgetary outlay of Rs. 6,940 crore
The company will initially supply prototypes to diverse customers to evaluate in purification processes for producing gene therapy drugs with a view to swift commercialization
The program seeks to boost regulatory predictability, support construction of US-based manufacturing sites
A nationwide network of over 1,000 accredited clinical trial sites will be created to accelerate drug development timelines and enhance research credibility
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
The state-of-the-art commercial production plant will be built on a 95-acre site in Saarlouis, acquired at the end of 2024
The successive PLI disbursements validate our disciplined execution and sustained commitment to strengthening India’s domestic pharmaceutical manufacturing capabilities
Plant 1 continues to serve as a core manufacturing hub for oral solid dosage forms
The Eugene facility, with more than 20 years of history, houses a 16,000-square-foot R&D lab and a newly constructed 30,000-square-foot manufacturing facility
Developed using STEERLife’s proprietary FragMelt continuous processing platform, the approval marks a major breakthrough in pharmaceutical manufacturing
Subscribe To Our Newsletter & Stay Updated
